Completed OBSERVATIONAL NCT01321567

Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis

Sponsor: Eisai Co., Ltd.

Conditions Refractory Reflux Esophagitis

Updated 9 times since 2017 Last updated: Jul 21, 2023 Started: Jan 1, 2011 Primary completion: Mar 1, 2013 Completion: Aug 1, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Refractory Reflux Esophagitis, this trial is completed. The trial is conducted by Eisai Co., Ltd. and has accumulated 9 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Aug 2023 — Jul 2024 [monthly]

Completed
Jan 2021 — Aug 2023 [monthly]

Completed

▶ Show 4 earlier versions

Oct 2018 — Jan 2021 [monthly]

Completed
Jun 2018 — Oct 2018 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eisai Co., Ltd.

Data source: Eisai Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abashiri, Japan , Abuta, Japan , Adachi City, Japan , Agatsuma, Japan , Ageo, Japan , Aichi, Japan , Aioi, Japan , Aira, Japan , Aisai, Japan , Akaiwa, Japan and 429 more locations